<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317911</url>
  </required_header>
  <id_info>
    <org_study_id>UKHD-2-520/2015</org_study_id>
    <nct_id>NCT04317911</nct_id>
  </id_info>
  <brief_title>Catheter Ablation for Atrial Fibrillation in Preserved Ejection Fraction</brief_title>
  <acronym>AFFECT</acronym>
  <official_title>Catheter Ablation for Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) displays high prevalence in heart failure with preserved ejection
      fraction (HF-PEF) and compromises prognosis of affected patients. This study aims to assess
      catheter ablation (CA) for AF in patients with HF-PEF compared to AF-patients without
      systolic or diastolic dysfunction. Primary endpoints are freedom from AF and quality of life
      at 1 year. Furthermore, the study is designed to elucidate mechanistic characteristics
      distinguishing arrhythmic substrate and predicting AF-recurrence in patients with HF-PEF. For
      this purpose, left atrial concentrations of biomarkers for inflammation, fibrosis and
      neurohumoral activation are determined and hemodynamic measurements are performed
      periprocedurally.

      Information on benefit from CA in these patients is necessary for clinical decision making
      and mechanistic investigations may point to tailored approaches in order to increase
      therapeutic efficiency.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical arrhythmia and holter-recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nTproBNP</measure>
    <time_frame>12 months</time_frame>
    <description>[ng/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T</measure>
    <time_frame>12 months</time_frame>
    <description>[pg/mL]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic left ventricular function in echocardiography</measure>
    <time_frame>12 months</time_frame>
    <description>LVEF [%]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic left ventricular function in echocardiography</measure>
    <time_frame>12 months</time_frame>
    <description>E/e'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PA-pressure in echocardiography</measure>
    <time_frame>12 months</time_frame>
    <description>[mmHg]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic function in stressechocardiography</measure>
    <time_frame>12 months</time_frame>
    <description>E/e'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute-walk-test</measure>
    <time_frame>12 months</time_frame>
    <description>[m]</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <description>Patients with preserved ejection fraction presenting for catheter ablation via of atrial fibrillation are included in this study and prospectively observed regarding arrhythmia-related, functional and biomarker-associated outcomes.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting for evaluation for CA of AF with a left ventricular systolic ejection
        fraction ≥50% are identified and invited to undergo further stratification. All patients
        are submitted to thorough clinical screening for signs and symptoms of heart failure,
        echocardiographic assessment of diastolic function and blood test for peripheral plasma
        levels of natriuretic peptides. Based on these parameters, patients with heart failure with
        preserved ejection fraction (HF-PEF) are identified according to current guidelines.
        Patients not meeting HF-PEF-criteria are included in the control group. Their data and
        follow-up results are gathered in a registry from which age- and gender-matched controls
        are extracted for comparison with respective matched HF-PEF-cases.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Left ventricular ejection fraction ≥50%

          -  Scheduled for catheter ablation of AF

        Exclusion Criteria:

          -  Significant valvular heart disease

          -  Coronary artery disease with &gt;70% stenoses or necessary coronary Intervention at time
             of recruitment

          -  Coronary intervention 60 days before recruitment

          -  Coronary bypass surgery 90 days before recruitment

          -  Cardiomyopathy or cardiac storage disease (e.g. amyloidosis)

          -  Reduced left ventricular ejection fraction

          -  Pericardiac disease

          -  Significant pulmonary hypertension

          -  Chronic obstructive pulmonary disease with home-oxygen-therapy, oral steroids,
             hospitalization due to exacerbations during the last 12 months before recruitment, or
             suspected severe pulmonary condition based on clinical evaluation

          -  Other non-cardiac conditions associated with limited physical capacity (adipositas
             permagna, severe anemia)

          -  Pregnancy

          -  Other limitations for adequate performance of stress echocardiography (e.g. orthopedic
             reasons)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Maura M Zylla, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg, Department of Cardiology (Prof. Dr. H.A. Katus)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maura M Zylla, Dr. med.</last_name>
    <email>maura.zylla@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dierk Thomas, Prof.Dr.med.</last_name>
    <email>dierk.thomas@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Department of Cardiology</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Zylla, Dr. med.</last_name>
      <email>maura.zylla@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Maura Zylla</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Catheter Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

